Nidhi S. Mundada

Nidhi S. Mundada

Auto-generated profile, based on publicly available information

Nidhi S. Mundada

Department of Bioengineering University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Neurotherapeutics
Verified
Journal Article
Open access
PDF file
BPBradley T. Peet
Bradley T. Peet
SSSalvatore Spina
Salvatore Spina
NMNidhi Mundada
Nidhi Mundada
RJRenaud La Joie
Renaud La Joie
Frontotemporal dementia encompasses a group of clinical syndromes defined pathologically by degeneration of the frontal and temporal lobes. Historically, these syndromes have been challenging to diagnose, with an average of about three years between the time of symptom onset and the initial evaluation and diagnosis. Research in the field of neuroimaging has revealed numerous biomarkers of the various frontotemporal dementia syndromes, which has provided clinicians with a method of narrowing the differential diagnosis and improving diagnostic accuracy. As such, neuroimaging is considered a core investigative tool in the evaluation of neurodegenerative disorders. Furthermore, patterns of neurodegeneration correlate with the underlying neuropathological substrates of the frontotemporal dementia syndromes, which can aid clinicians in determining the underlying etiology and improve prognostication. This review explores the advancements in neuroimaging and discusses the phenotypic and pathologic features of behavioral variant frontotemporal dementia, semantic variant primary progressive aphasia, and nonfluent variant primary progressive aphasia, as seen on structural magnetic resonance imaging and positron emission tomography.

4 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EZEhud Zeltzer
Ehud Zeltzer
DSDaniel R. Schonhaut
Daniel R. Schonhaut
NMNidhi S. Mundada
Nidhi S. Mundada
GBGanna Blazhenets
Ganna Blazhenets
JPJhony Mejia Perez
Jhony Mejia Perez
RJRenaud La Joie
Renaud La Joie
Amyloid-PET detects fibrillar β-amyloid deposits, a defining feature of Alzheimer’s disease. This technology has been used in research for over 20 years, and is now used in clinical practice to guide patient diagnosis and management. However, the real-world use of amyloid-PET may differ from research settings due to less standardized acquisition protocols, less experienced visual readers, and patients with more comorbidities, potentially compromising test accuracy. We evaluated the performance of amyloid-PET as used in a real-world clinical setting utilizing data collected via the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study. The study collected clinical amyloid-PET scans of older adults with cognitive decline acquired in 294 imaging facilities using three FDA-approved radiotracers. We centrally processed these scans using a PET-only processing pipeline and derived summary quantification of cerebral radiotracer retention measured on the Centiloid scale. We applied an a priori autopsy-based threshold of 24.4 Centiloids to quantitatively define scan positivity and compared this quantitative classification with binary visual reads performed by local radiologists or nuclear medicine physicians. 10,350/10,774 scans (96%) passed quality control and were successfully quantified. Median patient age was 75 (interquartile range 71, 80) years, 51% were females, 87% self-identified as White, 63% had mild cognitive impairment (vs. 37% with dementia), and 61% of scans were visually positive based on local reads. Centiloid values were higher in visually positive scans (median=74 [46, 99]) compared to scans locally read as negative (−2 [−13, 12]; p<0.001). Patients with dementia had higher Centiloids than those with mild cognitive impairment (57 [8, 91] vs. 34 [−2, 79]; p<0.001), consistent with a higher visual positivity rate (70% vs. 56%, respectively; p<0.001). Agreement between local visual reads and quantitative classification was 86.3% (95%CI: 85.7%, 87.0%), corresponding to Cohen’s Kappa of 0.715 (95%CI: 0.701, 0.729; p<0.001). Overall, 5,519 [53% of total] scans were positive by both visual read and quantification (V+/Q+); 3,416 [33%] were negative by both (V-/Q-), 813 [8%] were V+/Q-, and 602 [6%] were V-/Q+. Female sex, White race, and use of the radiotracers 18 F-flutemetamol and 18 F-florbetaben (compared to 18 F-florbetapir) were associated with higher visual-quantitative concordance. In conclusion, local visual reads showed high concordance with central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET as used in the real world and the use of quantification in clinical settings.

13 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NMNidhi S. Mundada
Nidhi S. Mundada
XLXueying Lyu
Xueying Lyu
CBChristopher A. Brown
Christopher A. Brown
NSNiyousha Sadeghpour
Niyousha Sadeghpour
EMEmily McGrew
Emily McGrew
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
INTRODUCTION: Clinical overlap between Alzheimer's disease (AD) and limbic‐predominant age‐related transactive response DNA binding protein 43 (TDP‐43) encephalopathy (LATE), combined with the absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut‐off and examined associated atrophy and cognitive profiles. METHODS: We studied cognitively impaired (CI) Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with T1‐magnetic resonance imaging (MRI) and amyloid‐ and tau‐positron emission tomography (PET). Participants were classified into suspected (s) AD+sLATE−, AD−sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole‐brain atrophy patterns and cognitive profiles were compared cross‐sectionally and longitudinally. Classification was validated in an autopsy cohort. RESULTS: AD+sLATE+ showed greater anterior hippocampal (AH) and amygdala atrophy than AD+sLATE−. AD−sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. DISCUSSION: A simple HV quartile cut‐off may help identify mixed AD/LATE pathology and support clinical trial enrichment. Highlights: Quartiles of HVs stratify CI individuals. Approach distinguishes suspected AD+sLATE–, AD–sLATE+, and AD+sLATE+ subgroups. The method is simple, scalable, and requires no complex modeling or biomarker panels. It enables practical identification of mixed pathology in clinical settings. It supports trial enrichment by excluding or targeting mixed pathology cases.

16 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
NMNidhi S. Mundada
Nidhi S. Mundada
XLXueying Lyu
Xueying Lyu
CBChristopher A. Brown
Christopher A. Brown
NSNiyousha Sadeghpour
Niyousha Sadeghpour
EMEmily McGrew
Emily McGrew
TIThe Alzheimer’s Disease Neuroimaging Initiative
The Alzheimer’s Disease Neuroimaging Initiative
Introduction Clinical overlap between Alzheimer’s disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), combined with absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut-off and examined associated atrophy and cognitive profiles. Methods We studied cognitively impaired ADNI participants with T1-MRI and amyloid- and tau-PET. Participants were classified into suspected (s) AD+sLATE-, AD-sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole-brain atrophy patterns and cognitive profiles were compared cross-sectionally and longitudinally. Classification was validated in an autopsy cohort. Results AD+sLATE+ showed greater anterior hippocampal and amygdala atrophy than AD+sLATE-. AD-sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. Discussion A simple HV quartile cut-off may help identify mixed AD/LATE pathology and support clinical trial enrichment.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NMNidhi S. Mundada
Nidhi S. Mundada
XLXueying Lyu
Xueying Lyu
NSNiyousha Sadeghpour
Niyousha Sadeghpour
CBChristopher D. Brown
Christopher D. Brown
EMEmily McGrew
Emily McGrew
DWDavid A. Wolk
David A. Wolk
Background: Overlap in clinical presentations, absence of well‐validated in‐vivo biomarkers for Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE), and frequent co‐occurrence with AD, complicates identifying mixed AD/LATE cases. Autopsy studies suggest greater hippocampal atrophy in AD patients with concomitant LATE. We aimed to identify patients along the AD continuum enriched for LATE by defining the lower quartile of hippocampal volume (HV) as a biomarker for possible LATE and explore atrophy patterns and cognitive profiles. Method: 164 cognitively impaired participants from ADNI with T1‐MRI and amyloid‐ and tau‐PET within 365 days were grouped based on HV quartiles (adjusted for age/intracranial volume) and amyloid status into suspected 1) AD‐only (HV>50th‐percentile, amyloid‐positive), 2) LATE‐only (HV<25th‐percentile, amyloid‐negative), 3) AD+LATE (HVFigure‐2B(II)). AD+LATE showed faster atrophy than AD, however, the effect weakened when controlling for tau (Figure‐2B(IV‐V). Cross‐sectionally, LATE‐only and AD+LATE group showed lower memory and language scores than AD‐only, even after controlling for tau (Figure‐3A); however, longitudinally, AD+LATE declined faster across all domains, differing from AD‐only when controlling for tau, suggesting a more aggressive disease (Figure 3B). Conclusion: Patients in lower quartile of HV on the AD continuum exhibit LATE‐like patterns, suggesting underlying LATE pathology. A simple HV percentile‐based metric may help identify patients with concomitant LATE and AD with potential relevance for clinical trials and anti‐amyloid therapies.

17 June 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NMNidhi S. Mundada
Nidhi S. Mundada
NSNiyousha Sadeghpour
Niyousha Sadeghpour
EMEmily McGrew
Emily McGrew
HTHannah L. Tucker
Hannah L. Tucker
INIlya M Nasrallah
Ilya M Nasrallah
LWLaura E. M. Wisse
Laura E. M. Wisse
INTRODUCTION: The anterior medial temporal lobe (MTL), including the entorhinal cortex (ERC) and Brodmann area 35 (BA35), is among the earliest cortical sites of tau pathology in Alzheimer's disease (AD), yet conventional image segmentation methods poorly capture these regions. METHODS: We applied an automated segmentation approach using an extended Automatic Segmentation of Hippocampal Subfields (ASHS) atlas, including anterior MTL subregions, in 448 Pennsylvania Alzheimer's Disease Research Center participants with magnetic resonance imaging, tau positron emission tomography (PET) ( n = 199), and/or plasma phosphorylated tau 217 (p‐tau217) ( n = 377). Amyloid beta (Aβ) positivity was defined using PET or plasma. RESULTS: Tau‐PET showed an anterior–posterior gradient, with highest uptake in BA35, ERC, and anterior hippocampus. Increased MTL tau‐PET uptake and plasma p‐tau217 were associated with cortical thinning localized to BA35 and ERC, even in cognitively unimpaired Aβ‐positive individuals. CONCLUSIONS: Anterior MTL subregions, especially BA35, show early vulnerability to tau‐related neurodegeneration. Extended anterior MTL parcellation improves localization of early tau‐associated structural changes and may facilitate biological staging in preclinical AD.